Clinical Trials Directory

Trials / Completed

CompletedNCT00898703

Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer

QUANTIFICATION OF CIRCULATING ENDOTHELIAL CELLS (CEC) AND PLASMA ANGIOGENIC FACTORS IN PATIENTS WITH BREAST CANCER

Status
Completed
Phase
Study type
Observational
Enrollment
50 (actual)
Sponsor
University of Arizona · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of blood in the laboratory from patients with current or previous cancer may help doctors learn more about biomarkers related to cancer. PURPOSE: This research study is looking at blood samples in women with breast cancer or a history of breast cancer.

Detailed description

OBJECTIVES: Primary * To compare peripheral blood (PB) concentrations of circulating endothelial cells (CEC) in women with measurable, active breast cancer to PB concentrations of CEC in a control population of women with a history of breast cancer who are currently without evidence of active disease. Secondary * To compare in women with measurable breast cancer the relationship between PB concentrations of CEC prior to and at 3 and 6 weeks following initiation of a new chemotherapy or hormonal therapy, and correlate these values with clinical response to treatment to determine if CEC can be used as a tumor marker or indicator of disease burden. * To compare PB concentrations of CEC to levels of plasma proteins associated with angiogenesis, including vascular endothelial growth factor, in women with active or a prior history of breast cancer. OUTLINE: Peripheral blood and plasma samples are collected for analysis of circulating endothelial cells (CEC) and angiogenic growth factor levels. Blood samples from patients initiating a new chemotherapy or hormonal therapy for breast cancer are collected at baseline and at 3 and 6 weeks following the start of treatment. CEC are quantified via flow cytometry and plasma angiogenic markers are assessed via ELISA. PROJECTED ACCRUAL: A total of 100 patients with active, measurable breast cancer and 100 patients with a prior history of breast cancer will be accrued for this study.

Conditions

Interventions

TypeNameDescription
OTHERflow cytometry
OTHERimmunoenzyme technique
OTHERlaboratory biomarker analysis

Timeline

Start date
2001-08-01
Primary completion
2007-03-01
Completion
2007-03-01
First posted
2009-05-12
Last updated
2012-12-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00898703. Inclusion in this directory is not an endorsement.